Immunitybio is trading at $8.35 (+5.03%), with no confirmed company announcement explaining the move.
- A November 3 report said founder Patrick Soon-Shiong’s comments about planned sepsis trials drew attention to Anktiva; shares had climbed nearly 1% overnight, but the report did not establish that the comments explain the full intraday gain.
- No confirmed earnings release or other company announcement explaining the move was verified in available sources, and the earnings date appears uncertain.